Literature DB >> 22358084

GET73 modulates rat hippocampal glutamate transmission: evidence for a functional interaction with mGluR5.

Luca Ferraro1, Sarah Beggiato, Maria Cristina Tomasini, Tiziana Antonelli, Antonella Loche, Sergio Tanganelli.   

Abstract

In the present study, the effects of the γ-hydroxybutyrate (GHB) analog GET73 on hippocampal glutamate transmission have been evaluated by an approach combining in vivo microdialysis with the in vitro evaluation of tissue slices. The microdialysis results indicated that local perfusion (60 min) with 10 nM - 1mM GET73 increased extracellular glutamate levels in the CA1 region of the hippocampus of freely moving rats in a concentration dependent manner. In tissue slices from the rat hippocampus, GET73 (1 μM - 10 μM) did not affect L-[(3)H]glutamate uptake, whereas treatment with 1 μM GET73 significantly increased K(+)-evoked, but not spontaneous, glutamate efflux. The GHB analog did not affect the increase in glutamate efflux induced by 100 μM and 300 μM NMDA. In contrast, 500 nM GET73, a concentration at which it is ineffective alone, partially but significantly counteracted the increase in K(+)-evoked glutamate efflux induced by 100 μM CHPG, an mGluR5 agonist. When 500 nM GET73 was coperfused with 100 μM MPEP, it amplified the decrease in K(+)-evoked glutamate efflux induced by the mGluR5 antagonist. Interestingly, the increase in K(+)-evoked glutamate efflux induced by 1 μM GET73 was counteracted by coperfusion with a low (10 μM) concentration of MPEP, which by itself is ineffective. Finally, 500 nM GET73 did not affect the reduction of K(+)-evoked glutamate efflux induced by the mGluR2/3 agonist LY379268. These findings demonstrate that the GHB analog GET73 significantly affects glutamate transmission in the hippocampus, and its profile of action differs from that of its parent compound.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22358084     DOI: 10.1016/s1734-1140(11)70700-9

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  5 in total

1.  A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; Victoria M Long; Harrison H Tran; Antonella Loche; Roberto Cacciaglia; Robert M Swift; Lorenzo Leggio
Journal:  Eur J Pharm Sci       Date:  2017-08-01       Impact factor: 4.384

2.  Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; Antonella Loche; Victoria M Long; Carla Lobina; Harrison H Tran; Roberto Cacciaglia; Robert M Swift; Giancarlo Colombo; Lorenzo Leggio
Journal:  J Psychopharmacol       Date:  2018-01-23       Impact factor: 4.153

3.  An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder.

Authors:  Carolina L Haass-Koffler; Roberta Perciballi; Molly Magill; Antonella Loche; Roberto Cacciaglia; Lorenzo Leggio; Robert M Swift
Journal:  Psychopharmacology (Berl)       Date:  2021-11-03       Impact factor: 4.530

4.  Anti-Alcohol and Anxiolytic Properties of a New Chemical Entity, GET73.

Authors:  Antonella Loche; Francesco Simonetti; Carla Lobina; Mauro A M Carai; Giancarlo Colombo; M Paola Castelli; Domenico Barone; Roberto Cacciaglia
Journal:  Front Psychiatry       Date:  2012-02-14       Impact factor: 4.157

5.  In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5.

Authors:  Sarah Beggiato; Andrea C Borelli; Maria C Tomasini; M Paola Castelli; Nicholas Pintori; Roberto Cacciaglia; Antonella Loche; Luca Ferraro
Journal:  Front Pharmacol       Date:  2018-04-05       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.